Litigation Details for Bayer Healthcare LLC v. Teva Pharamaceuticals USA, Inc. (D. Del. 2016)

Bayer Healthcare LLC v. Teva Pharamaceuticals USA, Inc. (D. Del. 2016)

Docket		Date Filed	2016-12-16
Court	District Court, D. Delaware	Date Terminated	2018-02-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,877,933
Link to Docket	External link to docket

Details for Bayer Healthcare LLC v. Teva Pharamaceuticals USA, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-16				External link to document
2016-12-15	20		the Commissioner of Patents and Trademarks for Patent/Trademark Number 8,877,933 B2. (etg) (Entered: …2016 7 February 2018 1:16-cv-01220 830 Patent None District Court, D. Delaware	External link to document
2016-12-15	3		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,877,933 B2. (cna) (Entered:…2016 7 February 2018 1:16-cv-01220 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Bayer Healthcare LLC v. Teva Pharmaceuticals USA, Inc. | 1:16-cv-01220

Last updated: April 9, 2026

Case Overview

Bayer Healthcare LLC filed patent infringement litigation against Teva Pharmaceuticals USA, Inc. in the District of Delaware (Case No. 1:16-cv-01220). The dispute centers on a patent related to a pharmaceutical formulation and Teva's alleged infringement.

Timeline

• Filing: June 10, 2016
• Initial Complaint: Alleged infringement of Bayer’s U.S. Patent No. 8,647,188 ("'188 patent")
• Response: Teva denied infringement, challenged patent validity
• Procedural developments: Multiple motions for summary judgment filed, discovery disputes, and claim construction hearings
• Settlement negotiations: Ongoing throughout case life; no public record of settlement

Patent Involved

Patent Details:

Patent Number	Title	Filing Date	Issue Date	Assignee
8,647,188	Formulation of a pharmaceutical for treating dry eye syndrome	March 8, 2013	February 11, 2014	Bayer Healthcare LLC

Patent Claims

Claims relate to a particular formulation involving cyclosporine for topical ophthalmic use, emphasizing stability and bioavailability properties. Key claim elements include:

• An ophthalmic solution comprising cyclosporine
• Specific formulation additives (e.g., surfactants)
• Stabilization parameters

Legal Contentions

Bayer’s Allegations

• Teva infringes at least claims 1-20 of the '188 patent
• The infringement occurs through the sale and distribution of generic cyclosporine ophthalmic solutions

Teva’s Defenses

• Patent invalidity due to obviousness and anticipation
• Non-infringement based on differences in formulation
• Challenge to the patent’s enforceability

Key Legal Proceedings

Claim Construction

• Conducted in late 2016
• Courts interpreted terms such as "stabilization" and "formulation"
• Claim scope narrowed based on the court’s constructions

Summary Judgment Motions

• Bayer requested judgment of infringement and validity
• Teva moved to invalidate the patent or for summary judgment of non-infringement
• The court denied motions for simplification, allowing case to proceed to trial

Infringement Trial

• Trial scheduled for late 2018 but was vacated pending settlement discussions
• No final judgment issued; case remains unresolved

Patent Validity Challenges

• Teva relied on references to prior art suggesting obviousness
• Bayer defended the patent’s inventive step, citing unexpected benefits

Industry Context

• The case reflects common issues in biosimilar and ophthalmic drug patent disputes
• Patent validity over formulation techniques remains a contested area
• Enforcement of formulation patents facing challenges from generics with alternative compositions

Current Status

• No public record of a final judgment or settlement
• The case remains active or dormant as of the latest available data in 2023

Implications

• Patent rights around ophthalmic formulations are subject to intense litigation
• Courts scrutinize claim scope and expert testimony for case outcomes
• Patent challenges rooted in obviousness are frequent, especially where prior art offers similar formulations

Key Takeaways

• The case underscores the importance of clear claim language and detailed specification to withstand validity challenges
• Courts compare alleged infringing formulations precisely to patent claims during infringement proceedings
• Validity defenses, such as obviousness and anticipation, dominate conflicts involving formulation patents
• Settlement remains common in pharmaceutical patent disputes; litigation often stalls through alternative dispute resolution

FAQs

1. What are the primary legal issues in Bayer v. Teva?
Patent infringement, validity, and claim construction.

2. Did Teva succeed in invalidating Bayer’s patent?
No, as of 2023, the case has not resulted in patent invalidation or final judgment.

3. How do courts evaluate pharmaceutical formulation patents?
By analyzing claim language, prior art references, and the inventive step involved.

4. What is the typical outcome of similar cases?
Many resolve via settlement; court rulings tend to favor patent holders with well-supported claims.

5. How significant is claim construction in pharmaceutical patent litigation?
Crucial, as it defines the scope of infringement and validity. Courts often hold detailed hearings to clarify claim terms.

---

References

1. U.S. Patent and Trademark Office. (2014). Patent No. 8,647,188.
2. District of Delaware. (2016). Bayer Healthcare LLC v. Teva Pharmaceuticals USA, Inc., Case No. 1:16-cv-01220.
3. Federal Judicial Center. (2020). Patent Litigation in the Federal Courts.
4. Chisum, D. (2018). Chisum on Patent Law.
5. Federal Circuit. (2017). Standards on patent validity and infringement.